BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.
暂无分享,去创建一个
O. Mortensen | M. Jäättelä | M. Egeblad | L. V. van Kempen | L. C. V. Kempen | Marja Jäättelä | Ole Hartvig Mortensen
[1] K. L. Pierce,et al. Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.
[2] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[3] M. Jäättelä,et al. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF‐7 breast carcinoma cells , 2000, International journal of cancer.
[4] J. Beijnen,et al. In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS. , 2000, International journal of pharmaceutics.
[5] Y. Yarden,et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase , 1999, Oncogene.
[6] S. Ménard,et al. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation , 1998, Oncogene.
[7] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[8] A. Ullrich,et al. Distinct characteristics of heregulin signals mediated by HER3 or HER4 , 1997, Journal of cellular physiology.
[9] J. Baselga,et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] C. Arteaga,et al. Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site* , 1997, The Journal of Biological Chemistry.
[11] M. Sliwkowski,et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] Y. Yarden,et al. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.
[13] J. Weber,et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases , 1997, Nature.
[14] Walter Gilbert,et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene , 1997, Nature.
[15] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[16] Dihua Yu,et al. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.
[17] M. Hung,et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. , 1996, Oncogene.
[18] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[19] Y. Yarden,et al. An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.
[20] A. Ullrich,et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.
[21] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[22] V. Dixit,et al. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. , 1995, Oncogene.
[23] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.
[24] A. Bridges,et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.
[25] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Sliwkowski,et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.
[27] D. Goeddel,et al. Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.
[28] Yosef Yarden,et al. Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.
[29] A. Ullrich,et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Fernö,et al. ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.